{"id":995903,"date":"2026-08-17T08:11:34","date_gmt":"2026-08-17T12:11:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/"},"modified":"2026-08-17T08:11:34","modified_gmt":"2026-08-17T12:11:34","slug":"evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/","title":{"rendered":"Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <b>EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion\u2019s AI-Immunology\u2122 platform<\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>Glioblastoma is characterized by high mortality rates and significant unmet medical needs. EVX-05 is being developed as a novel therapeutic approach to treat glioblastoma<\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>Evaxion is collaborating with a world-leading academic medical research institution, which is expected to conduct initial clinical testing of EVX-05<\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>Evaxion maintains its cash runway into second half of 2027 as its R&amp;D pipeline is refocused with the addition of EVX-05 while the EVX-03 program is discontinued<\/b>\n        <\/li>\n<\/ul>\n<p align=\"justify\">COPENHAGEN, Denmark, August 17, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, expands it pipeline of cancer vaccine programs with EVX-05 against the deadly brain cancer glioblastoma.<\/p>\n<p align=\"justify\">We are collaborating with experts from Duke University School of Medicine to develop EVX-05. This program targets endogenous retrovirus (ERV)-derived antigens shared between glioblastoma patients, which AI-Immunology\u2122 has unique capabilities in identifying. These ERV-antigens constitute a novel source of highly attractive targets for off-the-shelf cancer vaccines.<\/p>\n<p align=\"justify\">With its new therapeutic concept, EVX-05 is being developed as a novel therapeutic approach for glioblastoma. Current therapies are often inadequate, meaning glioblastoma remains one of the most aggressive and deadly cancers.<\/p>\n<p align=\"justify\">\u201cWe are delighted to transform our discoveries in glioblastoma into a promising new vaccine program with EVX-05, which could hold a significant therapeutic potential in area of massive unmet medical need. We have an outstanding collaboration with Duke University and now see the huge benefits of combining their extensive disease understanding and clinical expertise with the unique target discovery capabilities of AI-Immunology\u2122,\u201d says Birgitte R\u00f8n\u00f8, CSO and COO of Evaxion.<\/p>\n<p align=\"justify\">&#8220;Patients with glioblastoma continue to face limited treatment options and poor outcomes,\u201d said Mustafa Khasraw, M.D., professor at Duke University School of Medicine. \u201cThe potential of ERVs as therapeutic targets has long been acknowledged, if we can unlock this potential, it would be a significant advancement towards improving care.\u201d<\/p>\n<p align=\"justify\">\n        <b>World-leading expertise<\/b><br \/>\n        <br \/>Evaxion is currently undertaking optimization of a lead vaccine candidate for the EVX-05 program as part of advancing it towards initial clinical testing. This is expected to be carried out by Professor Khasraw and his team, allowing for world-leading clinical expertise and knowledge of patient needs to help guide clinical development. The collaboration also potentially allows a cost-efficient way for Evaxion to study EVX-05 in a clinical phase 1 trial.<\/p>\n<p align=\"justify\">EVX-05 builds on the same ground-breaking ERV-targeting concept as EVX-04, Evaxion\u2019s vaccine candidate against acute myeloid leukemia. This confirms the broad applicability of the concept across cancers where immunotherapies remain inadequate and conserved immunogenic antigens can be identified.<\/p>\n<p align=\"justify\">Both programs draw on learnings from the EVX-03 program, which has now been discontinued and removed from our R&amp;D pipeline as a matter of portfolio management. The costs related to EVX-05 are captured within Evaxion\u2019s existing budgets and hence does not impact on our cash runway, which continues to stretch into second half of 2027.<\/p>\n<p align=\"justify\">\n        <b>Conference call and webcast<\/b><br \/>\n        <br \/>This coming Thursday, August 20, Evaxion\u2019s Executive Management will host a conference call and webcast at 8.30 ET\/14.30 CET today, presenting our Q2 2026 business update and financial results as well as taking questions. EVX-05 will be one of the topics discussed.<\/p>\n<p align=\"justify\">To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_fl-vORwGqyGklamlQ9PXxs-WyO0vmX0_0_vugzec_9oFo1eU6pjQUkDK1qvaLCplCy6rOc9J7We7yLMwlEK7GbG7ANuqsHvS1Nhi68jHiGLJkLgAVX5yVkiIXaytHa72F807ZfMKSOekidteQb0kjahtexyg5vniTV5imPq9Zs=\" rel=\"nofollow\" target=\"_blank\">link<\/a> to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.<\/p>\n<p align=\"justify\">To join the webcast, please click on this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_fl-vORwGqyGklamlQ9PX53J5gax5OdhtGLfeW9R2Mc20oQE9SBsgTfMqb68pFMr3duwE9XVisiSknRRTbJu9F8m7PNmKS3HozpyrnZlOqM=\" rel=\"nofollow\" target=\"_blank\">link<\/a>. The webcast recording will be available on our website shortly after the event.<\/p>\n<p align=\"justify\">\n        <b>About glioblastoma<\/b><br \/>\n        <br \/>Glioblastoma is the most aggressive malignant primary brain tumor. It has an incidence rate of 3.19 per 100,000 persons in the United States and a median age of 64 years (National Institute of Health).<\/p>\n<p align=\"justify\">No cure exists for glioblastoma, and treatment outcomes remain poor: 50% of patients die approximately one year from diagnosis (New England Journal of Medicine, 2005).<\/p>\n<p align=\"justify\">\n        <b>Contact information<\/b>\u00a0<br \/>Evaxion A\/S<br \/>Mads Kronborg<br \/>Vice President, Investor Relations &amp; Communication<br \/>+45 53 54 82 96 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tuC7W6OV1CU4eDP_qrGeFhwjFArf99pQkJRlsnxnXjOGI4Q_uij1YqapR1w1a9r1dg7KxVmf7q3TAskQu-cGvx1DRyLkvusQMMj1XkVsbdA=\" rel=\"nofollow\" target=\"_blank\">mak@evaxion.ai<\/a><\/p>\n<p align=\"justify\">\n        <b>About Evaxion<\/b><br \/>\n        <br \/>Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology\u2122. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel drug candidates for cancer and infectious diseases.<\/p>\n<p align=\"justify\">With AI-Immunology\u2122 we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.<\/p>\n<p align=\"justify\">We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients\u2019 lives by providing innovative and targeted treatment options.<\/p>\n<p align=\"justify\">For more information about Evaxion, AI-Immunology\u2122 and our pipeline, please visit our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F1L4e8G9OQccTgirN14qAa2U4F9eRyYYATxTfmhyo4r5FODPnuritQuWBndXj8AVh1oiSt5xTbE5DbnxtYdtew==\" rel=\"nofollow\" target=\"_blank\">website<\/a>.\u00a0<\/p>\n<p align=\"justify\">\n        <b>Forward-looking statement<\/b>\u00a0<br \/>This\u00a0announcement contains forward-looking statements\u00a0within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.\u00a0The words\u00a0\u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201canticipate,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d and other words and terms of similar meaning\u00a0identify forward-looking statements.\u00a0Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,\u00a0the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our\u00a0business from other significant geopolitical and macro-economic events;\u00a0and other uncertainties affecting our business operations and financial condition.\u00a0For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F\u00a0and other filings\u00a0with the US Securities and Exchange Commission (SEC), which are available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3DPmqQFDD5PrM1ETk23pCaDZBqPMjzEFloKrBgF-Ae02I1wMJ3CfDohOZVILfQK3GBkpA8_Pu1ciwV7gnFMDsevXvm2bvx0DIc8v3R4w4c_cgYEhu7jn3jqjdcnDauigk1hcjLer4Uvat_naur16enQ6MMEUTAbuTPm-uMGd8dI2qYKXRXEc21cdy5whHLdw_Ear-_2sSp9174BwNzC5MbtfjH9hdDiiYzWf5BRZyUI=\" rel=\"nofollow\" target=\"_blank\"><b>www.sec.gov<\/b><\/a>.\u00a0We do not assume any obligation to update any forward-looking statements except as required by law.\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzkyMCM0MDI0ODg2MjEjMjI1MjA4Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/N2FkOGFmYTktYTkwNS00MjExLTliYzQtN2Y3ZjE1ODExMmM1LTEyNjM2NDAtMjAyNi0wOC0xNy1lbg==\/tiny\/Evaxion.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion\u2019s AI-Immunology\u2122 platform Glioblastoma is characterized by high mortality rates and significant unmet medical needs. EVX-05 is being developed as a novel therapeutic approach to treat glioblastoma Evaxion is collaborating with a world-leading academic medical research institution, which is expected to conduct initial clinical testing of EVX-05 Evaxion maintains its cash runway into second half of 2027 as its R&amp;D pipeline is refocused with the addition of EVX-05 while the EVX-03 program is discontinued COPENHAGEN, Denmark, August 17, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, expands &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-995903","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion\u2019s AI-Immunology\u2122 platform Glioblastoma is characterized by high mortality rates and significant unmet medical needs. EVX-05 is being developed as a novel therapeutic approach to treat glioblastoma Evaxion is collaborating with a world-leading academic medical research institution, which is expected to conduct initial clinical testing of EVX-05 Evaxion maintains its cash runway into second half of 2027 as its R&amp;D pipeline is refocused with the addition of EVX-05 while the EVX-03 program is discontinued COPENHAGEN, Denmark, August 17, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, expands &hellip; Continue reading &quot;Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-17T12:11:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzkyMCM0MDI0ODg2MjEjMjI1MjA4Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program\",\"datePublished\":\"2026-08-17T12:11:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\\\/\"},\"wordCount\":1102,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI1NzkyMCM0MDI0ODg2MjEjMjI1MjA4Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\\\/\",\"name\":\"Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI1NzkyMCM0MDI0ODg2MjEjMjI1MjA4Nw==\",\"datePublished\":\"2026-08-17T12:11:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI1NzkyMCM0MDI0ODg2MjEjMjI1MjA4Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI1NzkyMCM0MDI0ODg2MjEjMjI1MjA4Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program - Market Newsdesk","og_description":"EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion\u2019s AI-Immunology\u2122 platform Glioblastoma is characterized by high mortality rates and significant unmet medical needs. EVX-05 is being developed as a novel therapeutic approach to treat glioblastoma Evaxion is collaborating with a world-leading academic medical research institution, which is expected to conduct initial clinical testing of EVX-05 Evaxion maintains its cash runway into second half of 2027 as its R&amp;D pipeline is refocused with the addition of EVX-05 while the EVX-03 program is discontinued COPENHAGEN, Denmark, August 17, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, expands &hellip; Continue reading \"Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-17T12:11:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzkyMCM0MDI0ODg2MjEjMjI1MjA4Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program","datePublished":"2026-08-17T12:11:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/"},"wordCount":1102,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzkyMCM0MDI0ODg2MjEjMjI1MjA4Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/","name":"Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzkyMCM0MDI0ODg2MjEjMjI1MjA4Nw==","datePublished":"2026-08-17T12:11:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzkyMCM0MDI0ODg2MjEjMjI1MjA4Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NzkyMCM0MDI0ODg2MjEjMjI1MjA4Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-and-refocuses-rd-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evaxion expands and refocuses R&amp;D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/995903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=995903"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/995903\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=995903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=995903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=995903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}